Leuprolide acetate associated with final adult height exceeding mid-parental height in girls with central precocious puberty

This retrospective cohort study conducted at Chang Gung Memorial Hospital evaluated 73 girls diagnosed with central precocious puberty or early puberty. The follow-up period spanned from 2003–2023. All patients received depot leuprolide acetate at a dose of 3.75 mg every 4 weeks.

The primary outcome assessed whether final adult height exceeded mid-parental height. Results showed 39 patients achieved final adult height exceeding mid-parental height, accounting for 53.4% of the sample. Additionally, the study reported a 6.57 cm greater final adult height difference with a p < 0.05.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported. Key limitations include that long-term outcomes based on confirmed final adult height remain limited, particularly in Asian populations. Whether gonadotropin-releasing hormone agonist therapy enables patients to surpass their genetically predicted height potential has not been well established. Secondary outcomes included age at treatment initiation, bone age advancement, baseline height SDS, absolute height, height SDS during therapy, and growth velocity during therapy.

Practice relevance was not reported in the source material. Clinicians should consider the observational nature of the evidence when applying these findings to patient care. The study design prevents definitive causal conclusions regarding treatment efficacy. Further research is needed to confirm these observations.